HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintained a $90 price target.
June 17, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Cytokinetics and maintained a $90 price target.
The reiteration of a Buy rating and the maintenance of a $90 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100